entertainment -WSS

entertainment

author：hotspot 2025-08-12 08:27:37 - browse：6

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Long Covid needs a new name — and a new frame

WSS

'Investigate these claims': UFO transparency at center of House hearing

Will the IRA bring competition to the biologics market?

New lawsuit accuses health insurer Cigna of denying claims in bulk

A new crop of companies is reshaping the health data economy

Biden warns of ‘dark winter’ during final presidental debate

Will the FTC rein in IQVIA's health data empire?

focus

entertainment

Wikipedia

Heart attack and stroke risk calculators need revising

Device maker Teleflex to acquire urology company for $600M

In age of alternative facts, a scholarly course on calling out crap

PEPFAR is under serious threat — and so is global health

Walensky prepares to leave CDC — and Congress — behind

Regeneron agrees to White House price limits on anti

Anesthesiologist group: stop taking Ozempic before surgery

Why patients can’t get everything they want on drug pricing

Trump demands the U.S. pay no more for drugs than other countries … again

Democrats decry new health bill for going easy on private equity

Wikipedia

What it's like to live with paralysis for one psychologist

Biden warns of ‘dark winter’ during final presidental debate

Truvian presents data for its desktop blood

WATCH: Why do bright lights make us see spots?

UHS says company favors patients whose insurance pays more

Democrats decry new health bill for going easy on private equity

leisure time

focus

hotspot

explore